secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0001654954-23-014542
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata raises $2.26M via warrant exercise at reduced price; issues new warrants at $0.6511/share
--------------------------------------------------------------------------------

- $2.26M gross proceeds from immediate cash exercise of 3.47M existing warrants at reduced exercise price of $0.6511/share (was $2.82).
- New Series A warrants for up to 3.71M shares (5-year term) and Series B warrants for up to 3.24M shares (28-month term) issued.
- Closing expected Nov 20, 2023; stockholder approval required for exercise of new warrants under Nasdaq rules.
- H.C. Wainwright placement agent receives 7% cash fee, 1% management fee, and warrants for 243,047 shares at $0.8139.
- Net proceeds for general corporate purposes including R&D, clinical trials, and potential acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423014542/0001654954-23-014542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423014542/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-014542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer